Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer

crossref(2024)

Cited 0|Views3
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined